

Saturday, 15 May, 2021						
	Room 1			Room2		
8:00~8:45	Morning Seminar 1 (Sponsored by Takeda Pharmaceutical Company Limited.)			8:00~8:45	Morning Seminar 2 (Sponsored by Janssen Pharmaceutical K.K.)	
	Chair	Shinsuke Iida (Nagoya City University Graduate School of Medical Sciences)			Chair	Masahiro Kizaki (Saitama Medical Center, Saitama Medical University)
	Speaker	Shaji Kumar (Mayo Clinic Cancer Center in Rochester, Minnesota, USA) Role of NINLARO in management of myeloma :Today and tomorrow			Speaker	Nizar J. Bahlis (University of Calgary, Calgary, AB, Canada) Multiple myeloma and anti-CD38 antibody
8:45~10:25	Plenary Session 4: Immunotherapy: Molecular targeting approach to realize individualized medicine in multiple myeloma					
	Chair	Shinsuke Iida (Nagoya City University Graduate School of Medical Sciences)				
	Speakers	Noopur Raje (Massachusetts General Hospital Cancer Center, USA) Targeting BCMA in multiple myeloma and beyond		9:30~10:15	Sponsor Seminar 3 (Sponsored by Eisai Co., Ltd.)	
		Shaji Kumar (Mayo Clinic Cancer Center in Rochester, Minnesota, USA) Recent advances in the management of multiple myeloma			Chair	Akifumi Takaori-Kondo (Graduate School of Medicine, Kyoto University)
		Takashi Kanamori (Nagoya City West Medical Center, Japan) Cytogenetic risk / genome-based medicine in multiple myeloma			Speaker	Mamiko Sakata-Yanagimoto (University of Tsukuba, Japan) Molecular understanding of peripheral T-cell lymphomas; from the bench to bedside
		Takeshi Harada (Tokushima University Graduate School of Biomedical Sciences, Japan) Targeting osteoclasts and myeloma cells by CELMoDs plus zoledronic acid-inducible Th1-like gd T cells in combination with elotuzumab				
10:25~10:35	Break					
10:35~12:15	JSH-ASH Joint Session : Development of molecular targeting therapy for bone marrow failure and anemia			10:30~11:15	Sponsor Seminar 4 (Sponsored by Chugai Pharmaceutical Co., Ltd.)	
	Chairs	Hideo Harigae (Tohoku University School of Medicine)			Chair	Takanori Teshima (Hokkaido University Faculty of Medicine)
		Neal S. Young (National Institutes of Health (NIH))			Speaker	Koji Izutsu (National Cancer Center Hospital, Japan) Treatment Options for relapsed/refractory DLBCL
	Speakers	Neal S. Young (National Institutes of Health (NIH), USA) Biologic inferences from clinical outcomes: immunosuppression and stem cell stimulation in bone marrow failure syndromes				
		Catherine M. Broome (MedStar Georgetown University Lombardi Cancer Center, USA) Molecular targeting therapy for autoimmune hemolytic anemia				
		Takahiro Suzuki (Kitasato University School of Medicine, Japan) Emerging strategies for myelodysplastic syndromes				
Norio Suzuki (Tohoku University Graduate School of Medicine, Japan) Molecular mechanism of erythropoietin deficiency in kidney disease						
12:15~12:25	Break					
12:25~13:10	Luncheon Seminar 3 (Sponsored by Sanofi K.K.)			12:25~13:10	Luncheon Seminar 4 (Sponsored by AbbVie GK)	
	Chair	Hideo Harigae (Tohoku University School of Medicine)			Chair	Koichi Akashi (Kyushu University Graduate School of Medical Science)
	Speaker	Catherine M. Broome (MedStar Georgetown University Hospital, USA) Pathogenesis and diagnosis of autoimmune hemolytic anemias – AIHA international expert recommendation–			Speaker	Marina Konopleva (The University of Texas MD Anderson Cancer Center, USA) Changing the treatment paradigm in AML
13:10~14:50	Plenary Session 5 : Immunotherapy: Cancer immunotherapy development: from a different perspective					
	Chair	Hideto Tamura (Dokkyo Medical University Saitama Medical Center)				
	Speakers	Haidong Dong (Mayo Clinic Cnccr Center, Rochester, Minnesota, USA) The resilience of tumor-reactive T cell responses in patients with advanced cancers.				
		Takahiro Ochiya (Tokyo Medical University, Tokyo, Japan) Exosome-based immunomodulation in cancer				
		Koji Tamada (Yamaguchi University Graduate School of Medicine, Japan) Novel technologies to improve the efficacy of CAR-T cells				
		David Avigan (Beth Israel Deaconess Medical Center, USA) Integrating personalized cancer vaccines with immune based targeting of hematologic malignancies				
14:50~14:55	Closing Remarks					